Pharming Reports on Financial Results for the First Half of 2017

Pharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2017. CEO Sijmen de Vries comments:

“Our strategic decision to reacquire the commercial rights to sell RUCONEST in North America has significantly increased revenue and profit generation for the first half of the year compared to the first half of 2016.

Combined with ongoing growth in the number of US patients entering our full patient care plan, RUCONEST SOLUTIONS, and new European patients starting RUCONEST therapy with our recently introduced EU home use kit, we expect sales to increase in H2.

Our strategy of increasing market access in the US with our sales, market access, nursing and patient management teams, and in the EU with continued expansion of our direct commercialization efforts, is driving the growth in new patients using RUCONEST.

In March, the European Commission adopted the Commission Implementing Decision to amend the marketing authorisation for RUCONEST to include self-administration using the RUCONEST Administration Kit. This decision allows for self-administration of RUCONEST for acute HAE attacks by adolescents and adults with a new custom-designed RUCONEST Administration Kit in the comfort and privacy of their own homes or at any other place they choose, without the necessity of a health care professional being present. The Administration Kit is now available for use in various EU markets, following approval of the Educational Materials by the local authorities in those markets.

Based on the increased momentum in sales volumes, underlying improving trends in identifying and diagnosing patients, combined with better patient care and management practices, and a focus on specialty pharmacy customers, we expect to further increase sales. We will continue to control costs and investments to improve profitability and drive sustainable long-term growth. We continue to expect additional positive operating results for the remainder of the year.”

(Source: Pharming)

2017-07-27T16:38:29+00:00